On Demand: Recent Advancements in the Management of Obesity with a Focus on Pharmacotherapies

Through this course, you will gain a comprehensive understanding of recent advancements in the management of obesity with a focus on pharmacotherapies. National obesity experts engage in an interactive, case-based discussion on medications that are approved for chronic weight management. You will understand the mechanism of the new medications that act on gut hormone receptors such as the GLP-1 and GIP receptors, with practical tips on using these in clinical practice. You can also expect a preview of new agents in the pipeline.

Based on a live webinar held on May 23, 2024.

 

Target Audience

The target audience for this learning program will be U.S.–-based primary care and geriatric clinicians who treat adults. This includes internal medicine (IM) and family medicine (FM) physicians and residents, hospitalists, physician associates (PAs), nurse practitioners (NPs), and other advanced practice registered nurses (APRNs).

Learning Objectives

  • Describe the role of medications approved for chronic weight management in the treatment of obesity.
  • Outline the physiologic effect of the incretin hormones, including their effect on appetite and nutrient intake.
  • List common adverse effects and contraindications of the currently approved medications for chronic weight management.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Course opens: 
05/30/2024
Course expires: 
06/15/2025

Format & Estimated Time to Complete: Based on a webinar held on Thursday, May 23, 2024, 12:00pm to 1:30pm with Exam and Evaluation - 1.5 hours

Disclosure of Support: This activity is supported by an independent educational grant from Lilly and Novo Nordisk.

Disclosure Statement: 
All individuals in control of the content for an MMS accredited continuing education activity must disclose all financial relationships with ineligible companies within the past 24-months. The following individuals disclosed relevant relationships with ineligible companies.

Rebecca Andrick, D.O., F.O.M.A., D.A.B.O,M.
• Lilly, Stock

Jaime Almandoz, M.D., M.B.A., F.T.O.S.,D.A.B.O,M.
• Novo Nordisk, Advisor
• Eli Lilly and Company, Advisor
• Boehringer Ingelheim, Advisor

All relevant financial relationships have been mitigated prior to the beginning of this activity in accordance with ACCME and MMS policies.  For this activity, all other individuals in control of content did not disclose any relevant financial relationships with ineligible companies.

Activity Term:
Original Release Date: 5/30/2024
Review Date(s): N/A
Termination Date: 6/15/2025

Moderator:

 
Adam H. Gilden, M.D., M.S.C.E., D.A.B.O.M.
Associate Professor of Medicine, 
University of Colorado School of Medicine

Speakers:

Rebecca M. Andrick, D.O., F.O.M.A., D.A.B.O.M.
Founder, Weigh to Wellness, Denver, CO
Associate Professor at Rocky Vista University
College of Osteopathic Medicine

Jaime Almandoz, M.D., M.B.A., F.T.O.S., D.A.B.O.M.
Medical Director, Weight Wellness Program
Associate Professor of Medicine  
UT Southwestern Medical Center

NEJM Education Editor:
Ole-Petter R. Hamnvik, MB BCh BAO, MMSc, MRCPI
Program Director, Endocrinology Fellowship, Brigham and Women’s Hospital 
Associate Professor of Medicine, Harvard Medical School 
Education Editor, NEJM Group

Reviewers:

Joseph Peppe, MD
Family Medicine

Christine H. Bruce, DMSc, MHSA, PA-C
Associate Professor and Program Director, Penn State University Physician Assistant Program

Kristin Wason, MSN, AGPCNP, CARN
Addiction Clinical Educator: Office Based Addiction Treatment, Boston Medical Center
Nurse Practitioner, Assistant Professor: Boston University School of Medicine
Education Lead: Grayken Addiction Nurse Fellowship

Accreditation Statement:
The Massachusetts Medical Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement:
The Massachusetts Medical Society designates this live activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Academy of Family Physicians (AAFP)
The AAFP has reviewed Management and Treatment of Obesity in Primary Care: An Evolving Landscape Series, and deemed it acceptable for AAFP credit. Term of approval is from 04/25/2024 to 04/25/2025. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • This session Recent Advancements in the Management of Obesity with a Focus on Pharmacotherapies (5/23/2024) is approved for 1.5 live activity AAFP Prescribed credits.

American Academy of Physician Assistants (AAPA)
Management and Treatment of Obesity in Primary Care: An Evolving Landscape: This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 5.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 3/22/2024 to 6/20/2025. AAPA reference number: CME-2011143.
Live Webinar
This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Association of Nurse Practitioners (AANP)
Management and Treatment of Obesity in Primary Care: An Evolving Landscape: Live Webinar #2:
Recent Advancements in the Management of Obesity with a Focus on Pharmacotherapies
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.5 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 24046609. This activity was planned in accordance with AANP Accreditation Standards and Policies.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Please sign in or create an account to take the course.

To participate in this CME activity: 

(1) review the learning objectives, disclosure statement, and accreditation statements; 
(2) navigate through all course pages and/or view video(s); 
(3) complete exams/assessments and evaluation; 
(4) be sure to CLAIM your credit; and 
(5) view/print certificate.

If you need to stop in the middle of a course, you may return to the course at any time to finish.

Required Hardware/software

This platform works with most modern web browsers (e.g., Chrome, Internet Explorer, MS Edge, Safari).
A PDF reader, such as Adobe Acrobat Reader, will be required to participate in some courses.